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Abstract
Background: The emergence of Multi-drug resistant tuberculosis in pandemic proportions throughout the world
and the paucity of novel therapeutics for tuberculosis have re-iterated the need to accelerate the discovery of
novel molecules with anti-tubercular activity. Though high-throughput screens for anti-tubercular activity are
available, they are expensive, tedious and time-consuming to be performed on large scales. Thus, there remains an
unmet need to prioritize the molecules that are taken up for biological screens to save on cost and time.
Computational methods including Machine Learning have been widely employed to build classifiers for high-
throughput virtual screens to prioritize molecules for further analysis. The availability of datasets based on high-
throughput biological screens or assays in public domain makes computational methods a plausible proposition
for building predictive models. In addition, this approach would save significantly on the cost, effort and time
required to run high throughput screens.
Results: We show that by using four supervised state-of-the-art classifiers (SMO, Random Forest, Naive Bayes and
J48) we are able to generate in-silico predictive models on an extremely imbalanced (minority class ratio: 0.6%)
large dataset of anti-tubercular molecules with reasonable AROC (0.6-0.75) and BCR (60-66%) values. Moreover,
these models are able to provide 3-4 fold enrichment over random selection.
Conclusions: In the present study, we have used the data from in-vitro screens for anti-tubercular activity from a
high-throughput screen available in public domain to build highly accurate classifiers based on molecular
descriptors of the molecules. We show that Machine Learning tools can be used to build highly effective predictive
models for virtual high-throughput screens to prioritize molecules from large molecular libraries.
Background
Tuberculosis (TB) caused by Mycobacterium tuberculo-
sis, is one of the major causes of morbidity and mortal-
ity in the developing world. Tuberculosis manifests in
many clinical forms from an active disease state to clini-
cal latency that can extend for decades. It has been
reported that there have been 9.4 million new cases of
TB with an estimated global mortality of 1.7 million in
the year 2009 [1]. Recent reports suggest that a high
proportion, averaging about 85% cases have been
accounted to occur in Asia and Africa with India and
China alone accounting to 50% of the total burden of
disease [2]. Evidences also point to an increasing inci-
dence of drug-resistant TB over the past decade [3]. In
addition, its catastrophic synergy with Acquired Immune
Deficiency Syndrome (AIDS) have made it a major
health concern worldwide [4]. The present drugs used
in the first line therapy of tuberculosis has been discov-
ered at least half a century ago, and the unabated global
rise of tuberculosis calls fort h ed e v e l o p m e n to fn o v e l
tools and methods for fast and efficient identification of
novel molecules with anti-tubercular activities.
With the lack of comprehensive systems level under-
standing of the causative organism and its intricate bio-
logical pathways and control mechanisms, it has been
suggested that whole cell phenotypic screens offer a bet-
ter proposition in comparison with single gene based
biological screens [5]. The availability of methods for
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for many such datasets being made available in public
domain. With the very low hit rate for such high-
throughput biological screens, it has become inevitable
to prioritize molecules to be taken up for biological
screens. It has been suggested out that virtual screening
of large compound libraries using computational meth-
ods like machine learning techniques could be efficiently
employed as a complementary approach to phenotypic
screens in drug discovery [6-12]. The availability of
small molecule bio-assay datasets in public domain pro-
vide a valuable means to build predictive computational
models that can be potentially used to prioritize mole-
cules for biological assays from large digital databases
[13,14].
We have previously [15] used machine learning
approaches to classify inhibitors identified from bioassay
screens of Mycobacterium tuberculosis in Middlebrook
7H12 broth [16,17]. The 7H12 media (ADC (albumin,
dextrose and catalase) enriched Middlebrook 7H9
broth) allows rapid recovery of mycobacteria from clini-
cal specimens, sputum, and respiratory secretions. While
the ADC enrichment provides more sensitivity to the
microbial culture, albumin acts as a protective agent by
binding free fatty acids, which may be toxic to mycobac-
terium species and catalase destroys toxic peroxides that
may be present in the medium and dextrose acts as an
energy source. In our present study we make use of a
confirmatory screen that identifies novel anti-tubercular
inhibitors of Mycobacterium tuberculosis in 7H9 broth
supplemented with glycerol and tween 80 for improved
growth; the media is principally used for growth of axe-
nic cultures of mycobacteria. The library of compounds
used in current bioassay excluded known inhibitors
from previously pursued compounds and their analogs,
on which our earlier study was based.
Although classification methods using machine learn-
ing approach are valuable tools in rapid virtual screen-
ing of compound libraries [12,18], they have been
seldom used in TB drug discovery programmes [19-22].
Our present work marks an effort in this direction to
make predictive models for prioritization and/or discov-
ery of novel active molecules that can be taken up
further in the drug discovery pipeline for tuberculosis.
Results and discussion
The dataset (AID449762) used in this study is a confir-
matory bioassay screen to identify novel compounds
that inhibit Mycobacterium tuberculosis in 7H9 media.
The dataset consists of 3,27,561 tested compounds with
1937 actives, 3,12,901 inactives and rest are inconclusive
compounds. Inconclusive compounds were not consid-
ered in this study to avoid uncertainty in the predictive
ability of the generated models. A total of 179
descriptors were calculated (this information can be
found at the following link http://genome.igib.res.in/
Mtb_7H9/Additional_file1.zip) and data processing was
done as described in the “Methods” section. After
removing un-informative bit string descriptors (i.e. the
ones containing only 0’so r1 ’s throughout the dataset),
only 154 descriptors remained and were used for further
classification and analysis. The list of descriptors
removed after data processing is provided in Additional
file 1: Table S1. The processed file was then split into
training and test sets (this information can be found at
the following link http://genome.igib.res.in/Mtb_7H9/
Additional_file3.zip). The training set file was converted
to ARFF format and loaded in Weka. As the file size
was very large, Weka was started with a heap size of 8
GB to handle Out-Of-Memory exception.
Initial classification experiments were done with stan-
dard base classifiers only. All the models obtained with
t h eb a s ec l a s s i f i e r sh a da nF Pr a t ew e l lb e l o wo u r
threshold limit i.e. 20% however the resulting high
accuracies were not a good representation of our dataset
because it is highly imbalanced, so cost sensitivity was
introduced using cost matrix to produce a more reliable
predictive ability of the classifier in use. Misclassification
cost for False Negatives was raised incrementally so as
to stay in the upper limit of False Positives. Thus a
number of models were trained based on differential
cost settings. The FN cost that resulted in the best pre-
dictive models for each of the individual classifiers is
depicted in Table 1.
The performance statistics of best classification mod-
els obtained with each classifier are represented in Table
2. All the results reported here are based on indepen-
dent testing and not on the training. Since a number of
models were trained on each dataset using different cost
settings, best models of each dataset in each classifier
category were selected based on various binary classifi-
cation measurements. All generated models had a con-
trolled FP rate. ROC curve analysis is considered as one
of the best and reliable approach for performance char-
acterization of virtual screening protocols therefore, the
ROC curve and AUC values are widely employed for
evaluating the discriminatory power of virtual screens.
The ROC curve analysis from Figure 1 revealed that out
of the four classifiers used in this study, SMO covers
Table 1 Misclassification cost used for false negatives
with each classifier
Classifier Cost
SMO 110
Random Forest 14000
Naïve Bayes 35
J48 350
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by Random Forest, Naïve Bayes and J48. An AUC value
close to 1 is considered significant in data analytics. In
order to make out the classifier’s ability to efficiently
identify actual positive and negative labels, a measure of
Sensitivity (a.k.a. Recall-rate) and Specificity for each
dataset was used respectively (Figure 2). An optimal pre-
diction aims to achieve 100% sensitivity and specificity.
A l lc l a s s i f i e r sw e r eh i g h l ys p e c i f i ci nt h e i rp r e d i c t i o n s
with specificity more than 80% and in terms of sensitiv-
ity SMO appeared to be the most sensitive among all.
Though all the models built using the four state-of-
the-art classifiers had accuracies above 80% but due to
the class imbalance problem in the data, BCR was used
to assess the robustness of the models. A consistent
BCR gave a precise estimation of overall model effi-
ciency as it equally weights the errors within each class.
Though all models are observed to have equivalent pre-
dictive ability, SMO turns out to be the best among all
with high sensitivity, maximum ROC value and highest
BCR rate.
The general aim of any virtual screening method is to
retrieve a significant portion of true positives from a
database being screened over random compound selec-
tion. In order to quantify the enrichment produced by
in-silico screening, we calculated Enrichment Factor
(EF) on variable dataset sizes. Popular EFs for early
enrichment rates are usually calculated at 1%, 2%, 5%
and 10% of the screening database. The EF values
obtained with our best model i.e. SMO were 3.7 (EF1%),
4.9 (EF2%), 3.8 (EF5%) and 3.02 (EF10%). These values
suggest that our model is able to achieve 3-4 fold
enrichment over random screening. Thus for the given
dataset under study, SMO is proposed to be the best
classifier for identifying inhibitors from axenic culture of
Mycobacterium tuberculosis.
Conclusions
In the present analysis of publicly available bio-assay
datasets for anti-tubercular activity in vitro, we show
that machine learning approaches can be efficiently used
to build predictive classifiers for anti-tubercular activ-
ities. High AUC values and reasonable BCR rates sug-
gest that these predictive models can serve as an
effective filter to screen large chemical libraries. The
major caveat of this approach is that the prioritization
of the molecules are target-agnostic and may at times
would not have any biological correlate given the pre-
sent understanding of the biological processes and needs
to be used in conjunction with other molecular biology
techniques to decipher the targets and mechanisms of
action. The amenability of a wide variety of bio-assay
datasets now in public domain makes it possible to cre-
ate classifier models based on them. This offers the
potential to apply multiple models based on additional
properties like toxicity, bio-availability, metabolic pro-
cesses etc., in conjunction to filter large molecular
libraries in-silico before being taken up for biological
screens.
Methods
Biological assay data
The High Throughput Biological Screen (HTS) data of
molecules for anti-tubercular activity (Assay ID: 449762)
was obtained from the PubChem data repository main-
tained by the National Centre for Biotechnology Infor-
mation (NCBI) [23]. The HTS was based on
microdilution Alamar blue assay [24] adapted to 384-
well plate format and uses Middlebrook 7H9 broth with
glycerol as the growth media. The screen was performed
on a compound library which consisted of 3,27,561
compounds. The confirmatory screen (i.e. AID449762)
excluded previously known inhibitors from [16,17] and
Table 2 Statistics of best predictive models for
AID449762
Classifier* TP
rate
FP
rate
TN
rate
FN
rate
Accuracy ROC
area
BCR
#
CSC NB 47.30 19.50 80.50 52.70 80.28% 0.70 63.90
CSC RF 47.00 19.20 80.80 53.00 80.58% 0.712 63.90
CSC SMO 51.90 19.30 80.70 48.10 80.52% 0.748 66.30
Metacost
J48
40.60 19.10 80.90 59.40 80.62% 0.61 60.75
*CSC denotes CostSensitiveClassifier,
# BCR denotes Balanced Classification Rate
Figure 1 Receiver operating characteristic (ROC) curve plot of
all the models. A plot of ROC curve for all the classifiers. Among
all classifiers, SMO achieved the maximum value for area under the
curve (AUC) closely followed by Random Forest and Naïve Bayes.
J48 had the least AUC. The corresponding scalar AUC values can be
viewed in Table 2
Periwal et al. BMC Pharmacology 2012, 12:1
http://www.biomedcentral.com/1471-2210/12/1
Page 3 of 7consists of 3,12,901 compounds identified as inactives
and only 1937 compounds as actives of which only 117
compounds showed activity < = 1 μM. By the assay defi-
nition, compounds that showed > 30% inhibition for at
least one concentration in the dose response were
defined as “Active”. If the inhibition at all doses was <
30% in the Mtb assay, the compound was defined as
“Inactive”. In the primary screen a compound was
deemed “Inactive” if it had a percent inhibition <
70.31%. The chemical structures of both active and inac-
tive compounds were downloaded as SDF files (this
information can be found at the following link http://
genome.igib.res.in/Mtb_7H9/AID449762.tar.gz).
Molecular descriptors
Molecular Descriptors were generated for the dataset
using the freely available Windows based descriptor cal-
culation software PowerMV [25]. PowerMV provides a
software environment for viewing, descriptor generation
and hit evaluation and its capacity is only limited by
available memory. As the number of compounds (~0.3
Million) in the bioassay used in this study was very
large, the entire dataset file was split to smaller SDF
files using a perl script available from MayaChemTools
[26]. Each of the file was then loaded in PowerMV seri-
ally and a set of 179 2D-descriptors corresponding to
molecular features were calculated for all the com-
pounds in the dataset AID449762. These descriptors
correspond to 147 Pharmacophore fingerprints-bit string
descriptors based on bioisosteric principles, 24 Weighted
Burden number-continuous descriptors to measure one
of the three properties electro negativity, Gasteiger par-
tial charge or atomic lipophilicity, XLogP and 8 Proper-
ties-useful for judging the drug-like nature of a
molecule like H-bond donors, H-bond acceptors, mole-
cular weight, blood-brain indicator, XLogP etc. The
c o m p l e t el i s to ft h ed e s c r i p t o r su s e di sp r o v i d e da s
Additional file 1: Table S1. The descriptor files were
combined into a single CSV (comma separated values)
file. Bioactivity values were appended as the last index
labeled as ‘Outcome’ depicting the class attribute which
consists of nominal values ‘Active’ and ‘Inactive’.
Data pre-processing
The merged descriptor file was pre-processed by remov-
ing attributes having only one value throughout the
dataset i.e. bit-string fingerprints containing all 0’so ra l l
1’s in them. This was accomplished by applying an un-
supervised attribute filter available in the Weka suite of
Machine Learning algorithms [27]. Removing non-infor-
mative descriptors decreased the dimensionality of the
dataset. The dataset was ordered by class. Finally, a
bespoke perl script was used to split the data into 80%
training cum validation set and 20% test set. The train-
ing cum validation set was used to build classification
models. A cross-validation (CV) of 5-fold was used dur-
ing all model building runs. In each iteration of an n-
fold CV, one fold is used for testing and the other n-1
folds are used for training the classifier. The test results
are collected and averaged over all folds. This gives the
Figure 2 Sensitivity and Specificity plot of all models. The Sensitivity and Specificity plot of classifiers revealed an optimal prediction by all
models. All the classifiers performed uniformly having high and equal specificity values with SMO being slightly more sensitive than others.
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values.
Machine learning of the dataset
All classification and analyses were performed on the
Weka workbench. Weka is a popular open source Java
based software that contains implementations of a
diverse range of classification and clustering algorithms
and a number of other utilities for data exploration and
visualization with the flexibility of incorporating new or
customized classifiers and components. In this study we
present a comparative account of four state-of-the-art
classifiers namely Naïve Bayes, Random Forest, J48 and
SMO that are trained to build predictive models. A brief
description of these algorithms is given below:
Random Forest
Random Forests are a combination of tree predictors in
which multiple classification trees are constructed from
an independent identically distributed random input
vector. After a large number of trees are generated, each
tree in the forest gives a classification or votes for a
class and the most popular class gives the final classifi-
cation [28]. The main advantage of this method is that
it is fast while at the same time, capable of handling of
large input variables without over-fitting.
Sequential minimal optimization (SMO)
SMO is an implementation of Support Vector Machine
(SVM) that globally replaces all missing values and
transforms nominal attributes into binary ones. It also
normalizes all attributes by default. Unlike the classical
SVM algorithm which used numerical Quadratic Pro-
gramming (QP) as an inner loop, SMO uses an analytic
QP step [29]. An SVM is a hyperplane that separates a
set of positive examples from a set of negative examples
with maximum margin. SMO is conceptually simple,
easy to implement and faster in computation. Fitting
logistic regression models to the outputs of the SVM
could in addition provide probability estimates.
J48
J48 implements the decision tree learner algorithm C4.5.
It creates a tree data structure that can be used to clas-
sify new instances. The leaf nodes contain the class
label. Each internal node of the tree contains a test deci-
sion result which decides what branch to follow from a
particular node. The leaf nodes contain the class label
[30].
Naive Bayes
This classifier is based on a strong assumption that each
descriptor is statistically independent. It learns the con-
ditional probability of each descriptor given the class
label. Classification is performed by applying the Bayes
rule to compute the probability of a class given particu-
lar instance of descriptors and then predicts the class
with highest posterior probability [31]. It is one of the
most effective and simplest classifier.
Building classification models
One of the issues with high-throughput biological assays
is that the datasets are often skewed on imbalanced. A
dataset is termed imbalanced if at least one of the
classes is represented by significantly less number of
instances than the other. In high-throughput unbiased
biological assay datasets, the skew is often towards the
inactive set with the actives comprising a minority class.
This class imbalance adds to the complexity of the clas-
sification problem. Standard error-based classification
methods when applied to highly imbalanced data often
results in severely skewed predictions that can result in
excessively high false negative rate. Therefore, in recent
years many strategies have been proposed to derive clas-
sification rules for imbalanced data [32]. Introducing
misclassification cost on false predictions makes the
error-based classifiers cost-sensitive and increases the
true predictive ability of the classifier [33]. Setting of
misclassification cost is always arbitrary and no general-
ized rule exists to set the cost.
There are two ways of introducing misclassification
cost in classifiers, first to design customized cost sensi-
tive algorithms and second to build a wrapper class that
can convert existing base alg o r i t h mi n t oc o s ts e n s i t i v e
one. The later method is commonly referred to as meta-
learning [34]. In Weka meta-learning is used to intro-
duce cost sensitivity in base classifiers. MetaCost is
based on relabeling training instances with minimum
expected cost class and then applying the error-based
learner to the new training set, generating reliable prob-
ability estimates on training examples [35]. This imple-
mentation uses all bagging iterations when reclassifying
training data and works well for unstable data. CostSen-
sitiveClassifier deploys two methods that can be used to
introduce cost-sensitivity: reweighting training instances
according to the total cost assigned to each class; or
predicting the class with minimum expected misclassifi-
cation cost [36]. In our study we used the former
method and thus the MinimizedExpectedCost option
was set to false.
T h ec o m p l e t em e t h o d o l o g yto create predictive mod-
els that is implemented in the current study is depicted
in Figure 3.
Performance measures
Various performance measures were used to evaluate
t h er e s u l t s .T r u eP o s i t i v eR a t e( T P R )i sr a t i oo fp r e -
dicted true actives to actual number of actives (i.e. TP/
TP + FN), False Positive rate (FPR) is ratio of predicted
false actives to actual number of inactives (i.e. FP/FP +
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results to the true value. It can be calculated as (TP +
TN/TP + TN + FP + FN). Sensitivity (TP/TP + FN)
relates to the test’s ability to identify positive results
whereas Specificity (TN/TN + FP) relates to the test’s
ability to identify negative results. A test with high sen-
sitivity and specificity has a low error rate. The enrich-
ment factor (EF) represents one of the most prominent
performance descriptors in virtual screening. It takes
into account the enhancement of the hit rate by a vir-
tual screening protocol compared to a random selection.
It can be calculated as the fraction of active compounds
found divided by the fraction of screened library. A
Balanced Classification Rate (BCR) (0.5*(sensitivity +
specificity)) defined as mean of sensitivity and specificity
gives a combined criteria of measurement that gives a
balanced accuracy for unbalanced datasets. A Receiver
Operating Characteristic (ROC) curve is a graphical plot
of TPR vs. FPR for a binary classification system. ROC
space is defined by FPR and TPR on X and Y axes
respectively. The Area under Curve (AUC) value
reported by a ROC is equal to the probability that a
c l a s s i f i e rw i l lr a n kar a n d o m l yc h o s e np o s i t i v ei n s t a n c e
higher than a randomly chosen negative one.
Additional material
Additional file 1: Table S1. Descriptors List. Microsoft DOC file
containing a table detailing the list of initial number of total descriptors
calculated with PowerMv [25] and the ones removed after data
processing and their categorical division.
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